The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma
Abstract
Epigenetic regulation of gene transcription by small-molecule inhibitors of histone deacetylases (HDACs) is a novel cancer therapy. Vorinostat (suberoylanilide hydroxamic acid) is the first FDA-approved HDAC inhibitor for the treatment of cutaneous manifestations of cutaneous T-cell lymphoma (CTCL). Vorinostat was active against solid tumors and hematologic malignancies as intravenous and oral preparations in Phase I development. In two Phase II trials, vorinostat 400 mg/day was safe and effective with an overall response rate of 24-30% in refractory advanced patients with CTCL including large cell transformation and Sézary syndrome. The common side effects of vorinostat, which are similar in all studies, include gastrointestinal symptoms, fatigue and thrombocytopenia and the most common serious event was thrombosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866
The Sir2 Family of Protein Deacetylases
Blander, G., & Guarente, L. (2004) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.73.011303.073651 · Cited by 1,495
Gregoretti, I., Lee, Y.-M., & Goodson, H. V. (2004) · Journal of Molecular Biology · doi:10.1016/j.jmb.2004.02.006 · Cited by 1,456
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Self-citationRichon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
(2002) · PubMed · Cited by 732
Duvic, M., Hymes, K., Heald, P., Breneman, D., Martin, A. G., Myskowski, P., Crowley, C., Yocum, R. C., & for Members of the Bexarotene Worldwide Study Group (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2456 · Cited by 706
Self-citationKelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Butler, L. M., Agus, D. B., Scher, H. I., Higgins, B., Rose, A., Cordon‐Cardo, C., Thaler, H. T., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2000) · PubMed · Cited by 615
Apoptotic and autophagic cell death induced by histone deacetylase inhibitors
Shao, Y., Gao, Z., Marks, P. A., & Jiang, X. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408345102 · Cited by 605
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Butler, L. M., Zhou, X., Xu, W.-S., Scher, H. I., Rifkind, R. A., Marks, P. A., & Richon, V. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182372299 · Cited by 510
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Vonderheid, E. C., Bernengo, M. G., Burg, G., Duvic, M., Heald, P., Laroche, L., Olsen, E., Pittelkow, M., Russell-Jones, R., Takigawa, M., et al. (2002) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2002.118538 · Cited by 493
Self-citationGarcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Immunopathogenesis and therapy of cutaneous T cell lymphoma
Kim, E. J., Hess, S., Richardson, S. K., Newton, S., Showe, L. C., Benoit, B. M., Ubriani, R., Vittorio, C. C., Junkins-Hopkins, J. M., Wysocka, M., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24826 · Cited by 413
O'Connor, O. A., Heaney, M. L., Schwartz, L., Richardson, S., Willim, R., MacGregor-Cortelli, B., Curly, T., Moskowitz, C., Portlock, C., Horwitz, S., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.9679 · Cited by 404
The Pathogenesis of Mycosis Fungoides
Girardi, M., Heald, P. W., & Wilson, L. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032810 · Cited by 389
Kelly, W. K., & Marks, P. A. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0106 · Cited by 330
Histone deacetylase inhibitors: discovery and development as anticancer agents
Marks, P. A., & Dokmanovic, M. (2005) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.14.12.1497 · Cited by 318
He, L.-Z., Tolentino, T., Grayson, P., Zhong, S., Warrell, R. P., Rifkind, R. A., Marks, P. A., Richon, V. M., & Pandolfi, P. P. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11537 · Cited by 303
STAT proteins as novel targets for cancer drug discovery
Turkson, J. (2004) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.8.5.409 · Cited by 295
Vrana, J. A., Decker, R. H., Johnson, C. R., Wang, Z., Jarvis, W. D., Richon, V. M., Ehinger, M., Fisher, P. B., & Grant, S. (1999) · Oncogene · doi:10.1038/sj.onc.1203176 · Cited by 284
Rosato, R. R., Almenara, J. A., Dai, Y., & Grant, S. (2003) · PubMed · Cited by 267
Clinicopathological spectrum of mycosis fungoides
Kazakov, D., Burg, G., & Kempf, W. (2004) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/j.1468-3083.2004.00937.x · Cited by 262
Vorinostat for Treatment of Cutaneous Manifestations of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., He, K., Sridhara, R., Abraham, S., Booth, B. P., Verbois, L., Morse, D. E., Jee, J. M., Pope, S., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2672 · Cited by 262
Zhang, C., Richon, V., Ni, X., Talpur, R., & Duvic, M. (2005) · Journal of Investigative Dermatology · doi:10.1111/j.0022-202x.2005.23925.x · Cited by 242
Self-citationNimmanapalli, R., Fuino, L., Stobaugh, C., Richon, V., & Bhalla, K. (2003) · Blood · doi:10.1182/blood-2002-08-2675 · Cited by 222
Guo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., & Bates, S. E. (2004) · Blood · doi:10.1182/blood-2003-09-3068 · Cited by 186
Marchion, D. C., Bicaku, E., Daud, A. I., Richon, V., Sullivan, D. M., & Munster, P. N. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20045 · Cited by 184
Signal transducer and activator of transcription (STAT) signalling and T‐cell lymphomas
Mitchell, T. J., & John, S. (2005) · Immunology · doi:10.1111/j.1365-2567.2005.02091.x · Cited by 163
Sommer, V. H., Clemmensen, O. J., Nielsen, O., Wasik, M., Lovato, P., Brender, C., Eriksen, K. W., Woetmann, A., Kaestel, C. G., Nissen, M. H., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403385 · Cited by 162
Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines
Sakajiri, S., Kumagai, T., Kawamata, N., Saitoh, T., SAID, J. W., & Koeffler, H. P. (2005) · Experimental Hematology · doi:10.1016/j.exphem.2004.09.008 · Cited by 152
Immunopathogenesis and therapy of cutaneous T cell lymphoma
Kim, E. J. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200524826 · Cited by 147
Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy
Marks, P. A., & Jiang, X. (2005) · Cell Cycle · doi:10.4161/cc.4.4.1564 · Cited by 142
Almenara, J., Rosato, R., & Grant, S. (2002) · Leukemia · doi:10.1038/sj.leu.2402535 · Cited by 141
Clonal heterogeneity in mycosis fungoides and its relationship to clinical course
Vega, F., Luthra, R., Medeiros, L. J., Dunmire, V., Lee, S., Duvic, M. A., & Jones, D. M. (2002) · Blood · doi:10.1182/blood.v100.9.3369 · Cited by 137
Self-citationGarcia, A. E., Quinton, T. M., Dorsam, R. T., & Kunapuli, S. P. (2005) · Blood · doi:10.1182/blood-2005-05-1933 · Cited by 128
HLA-DR5 and DQB1*03 Class II Alleles Are Associated With Cutaneous T-Cell Lymphoma
Jackow, C. M., Breuer-McHam, J., Friss, A., Alvear, J., Reveille, J. R., & Duvic, M. A. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12363352 · Cited by 110
Self-citationRole of histone deacetylase inhibitors in the treatment of cancer (Review)
Mei, S., Ho, A. D., & Mahlknecht, U. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.6.1509 · Cited by 109
Histone deacetylase inhibitors – a new tool to treat cancer
Somech, R., Izraeli, S., & Simon, A. J. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2004.04.006 · Cited by 108
Histone Deacetylase Inhibitors: Latest Developments, Trends and Prospects
Moradei, O. M., Maroun, C. R., Paquin, I., & Vaisburg, A. (2005) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1568011054866946 · Cited by 84
Heider, U., Kaiser, M., Sterz, J., Zavrski, I., Jakob, C., Fleissner, C., Eucker, J., Possinger, K., & Sezer, O. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00546.x · Cited by 82
Butler, L. M., Liapis, V., Bouralexis, S., Welldon, K. J., Hay, S. J., Thai, L. M., Labrinidis, A., Tilley, W. D., Findlay, D. M., & Evdokiou, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21939 · Cited by 74
Rook, A. H., Gottlieb, S. L., Wolfe, J. T., Vowels, B. R., Sood, S., Niu, Z., Lessin, S. R., & Fox, F. E. (1997) · PubMed · Cited by 73
Lakshmikanthan, V., Kaddour‐Djebbar, I., Lewis, R. W., & Kumar, M. V. (2006) · International Journal of Cancer · doi:10.1002/ijc.21824 · Cited by 47
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S. R. S., Wang, J. G., Frankel, S., Lis, J., & Duvic, M. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.7500 · Cited by 42
Self-citationDuvic, M. A., & Zhang, C. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603465 · Cited by 36
Self-citationLedent, V., & Vervoort, M. (2006) · BMC Biology · doi:10.1186/1741-7007-4-24 · Cited by 33
Developing new drugs for the treatment of lymphoma
O’Connor, O. A. (2005) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2005.00470.x · Cited by 29
Research works printed but not linked: 16
- 10.1080/10428190410001693560 · DOI
- BERGER, 2002, Blood, 99, 2929, 10.1182/blood.V99.8.2929 · DOI
- ROOK, 1997, Clin. Exp. Immunol, 107, 16
- 10.1016/j.jmb.2004.02.006 · DOI · Paper page
- FURUMAI, 2002, Cancer Res, 62, 4916
- O’, 2005, Eur. J. Haematol. Suppl, 150
- BUTLER, 2000, Cancer Res, 60, 5165
- 10.1172/JCI200111537 · doi:10.1172/jci200111537 · Paper page
- KELLY, 2003, Clin. Cancer Res, 9, 3578
- GARCIA-MANERO, 2005, Blood, 106, 785a, 10.1182/blood.V106.11.785.785 · doi:10.1182/blood.v106.11.785.785
- DESAI, 2003, Anticancer Res, 23, 499
- BUTLER, 2000, Cancer Res, 60, 5165
- ROSATO, 2003, Mol. Cancer Ther, 2, 1273
- MEI, 2004, Int. J. Oncol, 25, 1509
- DUVIC, 2006, Blood, 108, 112a, 10.1182/blood.V108.11.112.112 · doi:10.1182/blood.v108.11.112.112
- OLSEN, 2006, ASCO Annual Meeting Proceedings, 24, 7500
Cited by
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
Histone deacetylase inhibitors: Potential in cancer therapy
Marks, P. A., & Xu, W. ‐. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22185 · Cited by 712
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008522107 · Cited by 363
Choi, K.-C., Jung, M. G., Lee, Y.-H., Yoon, J. C., Kwon, S. H., Kang, H.-B., Kim, M.-J., Cha, J.-H., Kim, Y. J., Jun, W. J., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2442 · Cited by 354
Metadata
- Authors
- Duvic, M., & Vu, J.
- Venue
- Expert Opinion on Investigational Drugs
- Publisher
- Informa Healthcare
- Published
- 2007-06-26
- Volume
- 16
- Issue
- 7
- Pages
- 1111-1120
- ISSN
- 1354-3784 (ISSN-L)
- 1744-7658
- OpenAlex
- W1968568016
- Cited by
- 344
- References
- 55
- FWCI
- 26.10
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.